Circulating intercellular adhesion molecule-1 in melanoma patients: induction by interleukin-2 therapy

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Intercellular adhesion molecule-1 (ICAM-1, CD54) is a cell surface molecule crucial for cell-cell interactions in immune responses.
• Soluble ICAM-1 (sICAM-1) presence in circulation may reflect inflammatory and immune processes.
• Melanoma treatment, particularly with high-dose IL-2, can induce significant systemic immune changes.

Purpose of the Study:

• To develop and utilize a specific enzyme-linked immunosorbent assay (ELISA) for quantifying soluble ICAM-1 in human serum.
• To investigate the levels of circulating ICAM-1 in healthy volunteers, melanoma patients, and patients undergoing high-dose IL-2 therapy.
• To explore potential correlations between circulating ICAM-1 levels, tumor burden, and cytokine induction during IL-2 treatment.

Main Methods:

• Development of a novel, specific enzyme-linked immunosorbent assay (ELISA) for soluble ICAM-1 detection.
• Serum samples were collected from healthy volunteers (n=5), melanoma patients (n=10), and patients receiving high-dose IL-2 for metastatic melanoma (n=8).
• Quantification of circulating ICAM-1 concentrations and assessment of associated cytokine levels (TNF-α, IFN-γ).

Main Results:

• No significant correlation was found between circulating ICAM-1 levels and tumor burden in melanoma patients.
• Melanoma patients treated with high-dose IL-2 exhibited a marked increase in circulating ICAM-1, up to 200% compared to pre-therapy levels (4-13 ng/ml).
• The observed elevation in circulating ICAM-1 during IL-2 therapy was associated with the induction of tumor necrosis factor-alpha and interferon-gamma.

Conclusions:

• Circulating ICAM-1 levels are significantly elevated during high-dose IL-2 immunotherapy for metastatic melanoma.
• The increase in sICAM-1 appears to be linked to the systemic inflammatory response induced by IL-2, evidenced by elevated TNF-α and IFN-γ.
• sICAM-1 may serve as a potential biomarker for monitoring immune activation in response to IL-2 therapy in melanoma.